Dabogratinib Establishes Initial Activity in FGFR3-Altered NMIBC
Tyra Biosciences reported initial open-label Phase II SURF302 results for oral dabogratinib in adults with FGFR3-altered low-grade, intermediate-risk non-muscle-invasive bladder cancer. At 60 mg once daily, 11 of 14 efficacy-evaluable participants responded at three…
